You are here

  • Home
  • Archive
  • Volume 29, Issue Suppl 4
  • P22 An exploratory safety and immunogenicity study of human papillomavirus (HPV16+) immunotherapy VB10.16 in women with high grade cervical intraepithelial neoplasia (HSIL; CIN 2/3)

Article info

Article menu
Download PDFPDF
Poster exhibition Day 1
P22 An exploratory safety and immunogenicity study of human papillomavirus (HPV16+) immunotherapy VB10.16 in women with high grade cervical intraepithelial neoplasia (HSIL; CIN 2/3)

Authors

Citation

Hillemanns P, Petry K, Böhmer G, et al
P22 An exploratory safety and immunogenicity study of human papillomavirus (HPV16+) immunotherapy VB10.16 in women with high grade cervical intraepithelial neoplasia (HSIL; CIN 2/3)
International Journal of Gynecologic Cancer 2019;29:A64-A65.

Publication history

  • First published November 1, 2019.
Online issue publication 
March 03, 2020

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.